Vertex Pharmaceuticals Inc

2026. g. 2. jūl. 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

2026. g. 1. jūl. 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

2026. g. 30. jūn. 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

2026. g. 29. jūn. 19:31 UTC

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

2026. g. 26. jūn. 20:04 UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

2026. g. 25. jūn. 20:02 UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

2026. g. 24. jūn. 23:26 UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026. g. 23. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.

2026. g. 22. jūn. 20:02 UTC

Vertex Pharmaceuticals is higher today, supported by a diverse pipeline in kidney disease and favorable market conditions following easing U.S.-Iran tensions.

2026. g. 18. jūn. 19:52 UTC

Vertex Pharmaceuticals shares are lower today as biotechnology stocks face pressure. Earlier in the session, shares peaked before reversing direction.

2026. g. 17. jūn. 19:54 UTC

Vertex Pharmaceuticals is rising amid a positive Biotechnology sector trend and favorable Federal Reserve interest rate decisions, boosting investor confidence in healthcare.

2026. g. 16. jūn. 23:16 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment is influenced by optimism over a potential U.S.-Iran peace deal.

2026. g. 15. jūn. 12:46 UTC

Vertex Pharmaceuticals is roughly flat in pre-market hours, maintaining a routine performance and remaining above its 20-day moving average.

2026. g. 12. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

2026. g. 11. jūn. 23:56 UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026. g. 10. jūn. 20:03 UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

2026. g. 9. jūn. 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

2026. g. 8. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

2026. g. 5. jūn. 23:06 UTC

Vertex Pharmaceuticals shares are trading lower in after-market hours, with no specific news identified. Broader market conditions may be influencing the stock's movement.

2026. g. 4. jūn. 20:02 UTC

RBC reiterated its Outperform rating on Vertex Pharmaceuticals with a $543 price target, contributing to shares advancing despite an earlier pullback.

2026. g. 3. jūn. 23:06 UTC

Vertex Pharmaceuticals shares are trading higher in after-market hours. No specific news was identified to explain this movement amid broader market volatility.

2026. g. 2. jūn. 20:03 UTC

Vertex Pharmaceuticals' FDA acceptance of povetacicept application fails to lift shares, which are trading lower and below their 20-day moving average.

2026. g. 1. jūn. 19:41 UTC

Vertex Pharmaceuticals' Biologics License Application for povetacicept accepted by the FDA. Shares are lower today amid broader market sentiment despite this milestone.

2026. g. 29. maijs 22:06 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, trading near the upper end of their one-month range and above their 20-day moving average.

2026. g. 28. maijs 20:02 UTC

Vertex Pharmaceuticals shares are higher today, continuing a steady upward trend since Wednesday. Broader market reactions to geopolitical tensions are influencing trading.

2026. g. 27. maijs 19:46 UTC

Truist Securities initiated coverage of Vertex Pharmaceuticals with a Buy rating and raised the price target to $542, contributing to today's price gain.

2026. g. 26. maijs 19:56 UTC

Vertex Pharmaceuticals shares are higher today, continuing recent upward momentum. No specific company news was identified to explain the price movement.

2026. g. 22. maijs 19:26 UTC

Vertex Pharmaceuticals shares are higher as Health Canada reviews suzetrigine, a new oral pain treatment. The stock shows modest gains since Thursday's close.

2026. g. 21. maijs 19:56 UTC

Vertex Pharmaceuticals shares rise as Health Canada reviews suzetrigine for acute pain treatment, marking a potential breakthrough in oral pain medication.